Jaguar Health’s Crofelemer accepted for ACG presentation

Jaguar Health (JAGX) says preliminary results from an open-label study in adult short bowel syndrome with intestinal failure (SBS-IF) using Crofelemer have been accepted for presentation at the annual American College of Gastroenterology meeting.